New authorizations to resume patient enrollment in Phase 3 studies of masitinib
14/09/2021 – AB Science announced that it has received new authorizations to resume patient enrollment in its Phase 3 studies of masitinib
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
